New Dual-Action Drug Aims to Combat Muscle Loss in Obesity Treatment
As GLP-1 receptor agonist medications continue to transform obesity treatment, researchers are working to address one of their most significant side effects: the loss of lean muscle mass. This undesirable consequence has become a central focus of ongoing clinical trials exploring next-generation therapies.
Lean muscle mass plays a critical role in overall health, contributing to daily mobility, proper metabolic function, bone density support, and effective weight management. When individuals with obesity use GLP-1 medications to reach a healthier weight, the overall weight loss includes both fat and muscle reduction. Research indicates that muscle loss can account for 20 to 30 percent of total body weight lost, depending on the specific drug and individual factors.
Survodutide: A Promising Approach to Muscle Preservation
The goal of future metabolism and weight loss drugs is to target fat stores with minimal impact on muscle mass. This is precisely the objective behind the Phase III SYNCRHONIZE-MASLD clinical trials investigating survodutide, a GLP-1 dual agonist manufactured by Boehringer Ingelheim.
How Survodutide Works
Survodutide functions similarly to other GLP-1 medications by controlling appetite and satiety. However, its supplemental glucagon agonist component goes a step further, not only helping to preserve muscle mass but also targeting specific types of fat most likely to cause long-term health problems.
The drug specifically addresses fat in the liver as well as visceral fat — the type that coats internal organs and poses the greatest risk to overall health when present in excess.
Clinical Trial Focus
The Phase 3 clinical trials of survodutide examined patients over a 48-week period. Participants had obesity or overweight with signs of nonalcoholic fatty liver disease, now known as metabolic dysfunction-associated steatotic liver disease (MASLD), accompanied by inflammation or fibrosis.
The study results suggest that maintaining lean muscle mass during significant weight loss is achievable with the right pharmacological combination, offering hope for safer, more effective obesity treatments in the future.
